AstraZeneca PLC (STO:AZN)
1,522.00
+4.50 (0.30%)
Sep 10, 2025, 11:59 AM CET
AstraZeneca Revenue
AstraZeneca had revenue of $14.46B USD in the quarter ending June 30, 2025, with 11.74% growth. This brings the company's revenue in the last twelve months to $56.50B, up 15.00% year-over-year. In the year 2024, AstraZeneca had annual revenue of $54.07B with 18.03% growth.
Revenue (ttm)
$56.50B
Revenue Growth
+15.00%
P/S Ratio
4.39
Revenue / Employee
$599.16K
Employees
94,300
Market Cap
2,357.83B SEK
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 54.07B | 8.26B | 18.03% |
Dec 31, 2023 | 45.81B | 1.46B | 3.29% |
Dec 31, 2022 | 44.35B | 6.93B | 18.53% |
Dec 31, 2021 | 37.42B | 10.80B | 40.58% |
Dec 31, 2020 | 26.62B | 2.23B | 9.16% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Swedish Orphan Biovitrum AB | 26.97B |
Sectra AB | 3.37B |
Getinge AB | 35.50B |
Camurus AB | 2.27B |
Medicover AB | 25.22B |
Asker Healthcare Group AB | 15.88B |
BioArctic AB | 1.86B |
AddLife AB | 10.44B |
AstraZeneca News
- 10 hours ago - AZN: New Regulations Aim to Enhance Drug Advertising Transparency - GuruFocus
- 20 hours ago - Trump's Biotech Playbook Ignites $350 Billion Investment Blitz - Benzinga
- 1 day ago - AstraZeneca Lung Cancer Combo Extends Patient Survival By Years In Key Study - Benzinga
- 2 days ago - AstraZeneca (AZN) Study Shows Enhanced Survival with TAGRISSO and Chemotherapy - GuruFocus
- 3 days ago - TN signs MoUs with Hinduja, AstraZeneca - The Times of India
- 5 days ago - Sanofi Hit With Shock As Flagship Drug Successor Disappoints Investors - Benzinga
- 5 days ago - AstraZeneca, Corning And More On CNBC's 'Final Trades' - Benzinga
- 6 days ago - Global drugmakers rush to boost US presence as tariff threat looms - Reuters